<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811940</url>
  </required_header>
  <id_info>
    <org_study_id>#6698</org_study_id>
    <secondary_id>1U01DA033310-01A1</secondary_id>
    <nct_id>NCT01811940</nct_id>
  </id_info>
  <brief_title>Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence</brief_title>
  <acronym>TACT2</acronym>
  <official_title>Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed protocol is a multi-site double-blind, placebo-controlled outpatient study of
      the safety and efficacy of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine
      dependence. 198 patients will be enrolled and 176 patients randomized in a 14-week trial. The
      proportion of participants achieving sustained cocaine abstinence for three consecutive weeks
      at the end of the study will be significantly greater for the combined pharmacotherapies
      group compared to the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that the combination of an agent that increased baseline
      dopamine signaling (amphetamine) with one that reduced cocaine-induced dopamine release
      (topiramate) will improve dopamine regulation and be associated with improved cocaine use
      outcomes. 99 subjects at each of the two sites whom meet criteria for cocaine dependence, and
      all other study inclusion and exclusion criteria will be assigned to the 14-week
      double-blind, placebo-controlled treatment trial. Subjects will be randomized to receive
      either placebo or MAS-ER and topiramate. This proposal will test the hypothesis that MAS-ER
      and topiramate will promote cocaine abstinence. Participants who are randomized to the
      combination medication arm will have their dose titrated to 60 mg MAS-ER daily (over 2 weeks)
      and 200 mg topiramate a day (over 6 weeks) and maintained on this dose through week 13 of the
      trial. During week 14, participants will be tapered off both medications. All participants
      will receive a supportive behavioral treatment that emphasizes study procedure adherence.
      Starting in week one, all patients will receive incentives for compliance with study
      procedures on an escalating reinforcement schedule similar to that developed previously and
      not contingent on urine results. The purpose of the lead-out is to blind patients to the
      exact point of medication discontinuation and to provide naturalistic data on the effects of
      medication discontinuation. Moreover, a 3 month follow-up will be conducted to determine what
      happens to cocaine use after treatment discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three Weeks of Cocaine Abstinence at End of Study</measure>
    <time_frame>assessed during 14 weeks of trial, presented for last 3 weeks</time_frame>
    <description>The number of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at the end of the study. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB) and corroborated by the urine toxicology samples collected 3 times per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any Three Consecutive Weeks of Abstinence During Study</measure>
    <time_frame>14 weeks of study or length of study participation</time_frame>
    <description>The proportion of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at any time during the 14 week trial. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB)and corroborated by the urine toxicology samples collected 3 times per week.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Adderall-ER and Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall-ER</intervention_name>
    <description>MAS-ER 60mg/day</description>
    <arm_group_label>Adderall-ER and Topiramate</arm_group_label>
    <other_name>Adderall extended release (MAS-ER)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate 100 mg bid.</description>
    <arm_group_label>Adderall-ER and Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 18-60 who meet DSM-IV criteria for cocaine
             dependence.

          -  Used cocaine at least 9 days in the past 28 days with at least weekly cocaine use.

          -  Able of giving informed consent and capable of complying with study procedures.

        Exclusion Criteria:

          -  Meets DSM-IV-TR criteria for bipolar disorder, schizophrenia or any psychotic disorder
             other than transient psychosis due to drug abuse.

          -  Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR
             supported by the SCID-I/P that in the investigator's judgment are unstable, would be
             disrupted by study medication, or are likely to require pharmacotherapy or
             psychotherapy during the study period. Individuals who are currently stable on a
             psychotropic medication for at least 3 months may be included if in the investigator's
             opinion the psychotropic medication the patient is taking is compatible with the study
             medication (mixed amphetamine salts plus topiramate) and does not entail serious risk
             of adverse effects from the drug interactions. Individuals cannot be on any
             psychostimulants or other contraindicated medications.

          -  Individuals with a history of seizures or unexplained loss of consciousness

          -  History of allergic reaction to candidate medications (amphetamine or topiramate).

          -  Individuals with significant current suicidal risk.

          -  Women who are pregnant, nursing, or failure in sexually active female patients to use
             adequate contraceptive methods.

          -  Unstable physical disorders which might make participation hazardous such as
             uncontrolled hypertension (SBP &gt; 140, DBP&gt; 90,or HR &gt; 100 when sitting quietly), acute
             hepatitis(patients with chronic mildly elevated transaminases &lt; 3x upper limit of
             normal are acceptable), or uncontrolled diabetes.

          -  Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG, cardiac symptoms, fainting, open-heart surgery and/or arrhythmia, and
             family history of ventricular tachycardia/sudden death.

          -  Individuals with use of carbonic anhydrase inhibitors

          -  History of glaucoma

          -  History of kidney stones

          -  Use of drugs that may be additive to the bicarbonate lowering effects of topiramate

          -  Body Mass Index (BMI) &lt; 18kg/m2

          -  History of failure to respond to a previous adequate trial of either of the candidate
             medications for cocaine dependence

          -  Individuals physiologically dependent on any other drugs (excluding nicotine or
             cannabis) which require medical intervention

          -  Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other
             penalties,etc.) to participate in substance abuse treatment program

          -  Individuals with a current history (within the past 6 months) of amphetamine abuse or
             dependence including amphetamines such as methamphetamine and MDMA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyle Kampman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stars.columbia.edu</url>
    <description>stars website</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <results_first_submitted>August 16, 2018</results_first_submitted>
  <results_first_submitted_qc>September 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2018</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>adderall</keyword>
  <keyword>topiramate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT01811940/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT01811940/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>169 individuals enrolled in the trial and entered a 1 week placebo lead-in. 42 participants were not randomized due to several reasons including 16 being considered to be placebo-responders and 18 being lost to follow-up. 127 participants were then randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adderall-ER and Topiramate</title>
          <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
Adderall-ER: MAS-ER 60mg/day
Topiramate: Topiramate 100 mg bid.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adderall-ER and Topiramate</title>
          <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
Adderall-ER: MAS-ER 60mg/day
Topiramate: Topiramate 100 mg bid.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="8.4"/>
                    <measurement group_id="B2" value="46.4" spread="8.4"/>
                    <measurement group_id="B3" value="46" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High School or less</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some College</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>College or graduate school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>employment status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Full-time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Part-time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed/Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently married</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Three Weeks of Cocaine Abstinence at End of Study</title>
        <description>The number of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at the end of the study. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB) and corroborated by the urine toxicology samples collected 3 times per week.</description>
        <time_frame>assessed during 14 weeks of trial, presented for last 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adderall-ER and Topiramate</title>
            <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
Adderall-ER: MAS-ER 60mg/day
Topiramate: Topiramate 100 mg bid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Three Weeks of Cocaine Abstinence at End of Study</title>
          <description>The number of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at the end of the study. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB) and corroborated by the urine toxicology samples collected 3 times per week.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Three Consecutive Weeks of Abstinence During Study</title>
        <description>The proportion of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at any time during the 14 week trial. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB)and corroborated by the urine toxicology samples collected 3 times per week.</description>
        <time_frame>14 weeks of study or length of study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adderall-ER and Topiramate</title>
            <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
Adderall-ER: MAS-ER 60mg/day
Topiramate: Topiramate 100 mg bid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Any Three Consecutive Weeks of Abstinence During Study</title>
          <description>The proportion of participants in each study arm achieving sustained cocaine abstinence for three consecutive weeks at any time during the 14 week trial. This will be measured by self reported cocaine use on the daily Time line Follow Back (TLFB)and corroborated by the urine toxicology samples collected 3 times per week.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>collected during 14 weeks of trial or length of participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adderall-ER and Topiramate</title>
          <description>Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
Adderall-ER: MAS-ER 60mg/day
Topiramate: Topiramate 100 mg bid.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>inpatient rehabilitation</sub_title>
                <description>patient voluntarily entered an inpatient rehabilitation program.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>leg swelling/pain</sub_title>
                <description>One participant presented to the ER with pain and swelling in both legs. He was admitted for 48 hours for observation in the hospital and treated with antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <description>One patient was hospitalized for 48 hours due to an exacerbation of preexisting asthma. Upon receiving treatment, the symptoms subsided. Hospitalization was not considered related to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>increased blood pressure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>increased heart rate</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>muscle aches</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frances R. Levin, M.D.</name_or_title>
      <organization>NYSPI</organization>
      <phone>646-774-6137</phone>
      <email>Frances.levin@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

